IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody

Myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders characterized by proliferation and hyperplasia of maturing myeloid cells in bone marrow (BM). Characteristic genetic alterations are found in the majority of MPN patients, including BCR-ABL1 fusion in all chronic myelogeneous

[1]  H. Zentgraf,et al.  Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. , 2010, Leukemia research.

[2]  R. Kusec,et al.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.

[3]  Jih-Luh Tang,et al.  Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. , 2010, Blood.

[4]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[5]  A. Green,et al.  Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.

[6]  O. Abdel-Wahab,et al.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.

[7]  H. Zentgraf,et al.  Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.

[8]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[9]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[10]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[11]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[12]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.